ObsEva Announces Corporate Updates
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland– May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to its amended and restated securities purchase agreement (Securities Purchase Agreement) with certain funds and accounts managed by JGB Management, Inc. (JGB), which is structured to provide up to $135 million in borrowing capacity, available in nine tranches.
The third tranche under the Securities Purchase Agreement was due to be funded on May 25, 2022. However, the tranche has not been funded as a result of ObsEva not meeting the funding condition that its volume-weighted average share price would not trade below $3.00 per share for five or more trading days during the 30 days prior to the funding date for the third tranche. Pursuant to the Amendment Agreement, JGB has agreed to waive its right to terminate its obligation to fund future tranches under the Securities Purchase Agreement, which JGB would be entitled to as a result of the failure to meet the share price funding condition for the third tranche. In exchange, ObsEva has agreed to further restrictions on the existing account control agreement in favor of JGB, which secures the Securities Purchase Agreement. JGB also retains the right, at its sole option, to fund the third tranche at any time prior to the fourth tranche funding date, which is August 23, 2022. Except as noted, the terms of the Securities Purchase Agreement and ancillary agreements, including with respect to future tranches, remained unchanged. Further information with respect to the amendment to the convertible note financing agreement will be provided in a Form 6-K filed by ObsEva with the Securities and Exchange Commission on May 27, 2022.
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
CautionaryNote Regarding Forward Looking Statements of ObsEva SA
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include statements regarding the potential to raise funds in the future, including the availability of future tranches under the Securities Purchase Agreement, and the use of such fund from future fundraisings or from the financing agreement with JGB. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include the ability of the ObsEva to meet the conditions required to fund future tranches under the Securities Purchase Agreement, uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the ongoing novel coronavirus outbreak and other geopolitical events, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with Securities and Exchange Commission (SEC) on March 10, 2022, in the Report on Form 6-K filed with the SEC on May 17, 2022 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and, except as required by law, ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
CEO Office contact
+41 22 552 1550
+1 (917) 969-3438
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Monthly information related to total number of voting rights and shares composing the share capital _June 30, 2022.7.7.2022 18:00:00 CEST | Press release
Monthly information related to total number of voting rights and shares composing the share capital _June 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut(1) voting rights Total of net (2) voting rights December 31, 202131 018 55332 518 33932 515 839January 31, 202231 018 55332 518 33932 515 839February 28, 202231 018 55332 518 54732 516 047March 31, 202231 018 55332 518 54732 516 047April 30, 202231 018 55332 518 54732 516 047May 31, 202231 018 55332 518 54732 516 047June 30, 202231 018 55332 520 10732 517 607 (1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of g
KBC Group: KBC completes acquisition of Raiffeisen Bank International's Bulgarian operations7.7.2022 17:45:00 CEST | Press release
Press Release Outside trading hours – Regulated information* Brussels, Sofia, 7 July 2022 (5.45 p.m. CEST) KBC completes acquisition of Raiffeisen Bank International's Bulgarian operations Today, KBC Bank and Raiffeisen Bank International (‘RBI’) completed the deal announced on 15 November 2021 concerning the acquisition of 100% of the shares of Raiffeisenbank (Bulgaria) EAD, which is responsible for the banking operations of RBI in Bulgaria. The transaction also includes Raiffeisenbank Bulgaria’s fully owned subsidiaries Raiffeisen Leasing Bulgaria, Raiffeisen Asset Management (Bulgaria), Raiffeisen Insurance Broker and Raiffeisen Service. The acquisition, worth a total of 1 009 million euros paid in cash, reflects the quality of the Raiffeisen franchise in Bulgaria and the potential for synergy. The transaction will have a capital impact of around -1 pp on KBC Group’s CET1 in 3Q2022. Raiffeisenbank (Bulgaria) has systematically developed its banking activities since entering the mark
Volta Finance Limited - Dividend Declaration7.7.2022 17:12:32 CEST | Press release
Volta FinanceLimited (VTA/VTAS) Dividend Declaration NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Guernsey, 7 July 2022 Volta Finance Limited ("the Company") hereby announces a second interim dividend for the financial year commencing 1 August 2021. The Company announces that it has declared a quarterly interim dividend of €0.13 per share payable on 28 July 2022 amounting to approximately €4.75 million, equating approximately to an annualised 8% of net asset value. The ex-dividend date is 14 July 2022 with a record date of 15 July 2022. The Company has arranged for its shareholders to be able to elect to receive their dividends in either Euros or Pounds Sterling. Shareholders will, by default, receive their dividends in Euros, unless they have instructed the Company’s Registrar, Computershare Investor Services (Guernsey) Limited (“Computershare”), to pay dividends in Pounds Sterling. Such instructions may be given to Computershare eith
Maha Energy AB har underrättats om att kontrakterad borrigg i Oman har dragits tillbaka7.7.2022 15:45:00 CEST | Pressemelding
Maha Energy AB (publ) har underrättats av Global Business Services (“GBS”) att den kontrakterade borriggen GBS-1 (tidigare OGI-4) inte längre kommer att vara tillgänglig för Maha Energy i Oman. Detta innebär att den planerade borrstarten av de första sex brunnarna på Mafraqfältet försenas. GBS har meddelat Maha Energy att de inte kan leverera borriggen GBS-1 (tidigare OGI-4) främst på grund av tekniska brister som upptäckts under inspektioner strax innan mobiliseringen. Maha arbetar nu på att hitta alternativa lösningar, men detta innebär att borrningen av de sex brunnarna på Mafraq kommer att försenas. En reviderad tidplan kommer att meddelas så snart som ytterligare information finns tillgänglig. ”Då vi arbetat väldigt hårt för att få allt på plats och starta borrningarna innan den sista juni är vi mycket besvikna över att GBS nu beslutat att inte leverera den kontrakterade borriggen i sista minuten. Men eftersom borrplatser och all annan borrutrustning nu står klart så är vi redo fö
Maha Energy AB has been notified that contracted drilling rig has been withdrawn in Oman7.7.2022 15:45:00 CEST | Press release
Maha Energy AB (publ) has been notified by Global Business Services (“GBS”) that the contracted GBS-1 (formerly OGI-4) drilling rig will no longer be available for Maha Energy in Oman. This means that the planned start of the drilling of the six first wells on the Mafraq field will be delayed. GBS has notified Maha Energy that they are unable to deliver the drilling rig GBS-1 (formerly OGI-4) primarily due to technical deficiencies uncovered during pre-mobilisation inspections. Maha is now evaluating alternative options, but this means that the drilling of the six wells on Mafraq will be delayed. A revised schedule will be announced as soon as further information is available. Jonas Lindvall, CEO at Maha comments: “We have been working hard to ensure all material and equipment were available for a June 30 spud, so it is very disappointing that GBS has decided to withdraw the contracted drilling rig this late in the game. Everything else is in place so once we find a replacement drillin